Oasys Water Culminates Year with New Partnerships and Sale of World’s Largest, Most Capable Forward Osmosis System

Oasys Water Culminates Year with New Partnerships and Sale of World’s Largest, Most Capable Forward Osmosis System

December 12, 2013

Oasys Water, a world leader in innovative solutions for water treatment and desalination, today announced that they have recently signed an exclusive sales agreement with National Oilwell Varco, L.P. (NOV), a leading global provider of equipment and services used in the oil and gas market.

T2 Biosystems Strengthens Management Team as Company Prepares for Launch of Flagship T2CandidaTM Diagnostic Test

T2 Biosystems Strengthens Management Team as Company Prepares for Launch of Flagship T2CandidaTM Diagnostic Test

December 11, 2013

--Sarah Kalil Named COO; Steven Scampini as VP of Engineering--

Mascoma’s Technology Surpasses One Billion Gallons

Mascoma’s Technology Surpasses One Billion Gallons

December 11, 2013

– Mascoma’s consolidated bioprocessing (CBP) technology surpasses 1 billion gallons of ethanol produced; MGT® yeast products rapidly gain market penetration in renewable fuels market –

Agios Advances Cancer Metabolism Collaboration with Celgene

Agios Advances Cancer Metabolism Collaboration with Celgene

December 11, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 11, 2013-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced an extension of one additional year to the period of exclusivity for their strategic cancer metabolism collaboration with Celgene Corporation (NASDAQ: CELG).

Selecta Biosciences Announces Allowance of the First in a Series of Patents on the Induction of Antigen-Specific Immune Tolerance Using Selecta’s Novel Immunotherapies

Selecta Biosciences Announces Allowance of the First in a Series of Patents on the Induction of Antigen-Specific Immune Tolerance Using Selecta’s Novel Immunotherapies

December 9, 2013

Watertown, Mass. — December 9, 2013 – Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, today announced that the US Patent and Trademark Office (USPTO) has allowed the issuance of a Selecta owned patent with the title “Tolerogenic Synthetic Nanocarriers For Inducing Regulatory B Cells”, the first in a series of patent filings on antigen-specific tolerogenic immunotherapies.

Selecta Biosciences Announces Successful Pre-clinical Study of SEL-201 As An Antigen-Specific Immune Tolerance Treatment for Patients Receiving Factor VIII Therapy

Selecta Biosciences Announces Successful Pre-clinical Study of SEL-201 As An Antigen-Specific Immune Tolerance Treatment for Patients Receiving Factor VIII Therapy

December 9, 2013

Presentation of Data at the ASH 2013 Annual Meeting

Receptos and Ono Pharmaceuticals Expand Collaboration Agreement to Include Transfer of Receptos GPCR Technology Platform

Receptos and Ono Pharmaceuticals Expand Collaboration Agreement to Include Transfer of Receptos GPCR Technology Platform

December 10, 2013

SAN DIEGO (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT) announced today that Ono has elected to amend and expand the existing collaboration agreement between the parties to include transfer to Ono of the Receptos G-protein-coupled receptor (GPCR) technology platform, a proprietary high resolution protein crystal structure determination technology which enables rational drug design for the GPCR therapeutic target class.

Saudi Aramco Energy Ventures LLC Announces an Equity Investment into Novomer Inc.

Saudi Aramco Energy Ventures LLC Announces an Equity Investment into Novomer Inc.

December 10, 2013

Dhahran, Saudi Arabia and Waltham, Massachusetts – Saudi Aramco Energy Ventures LLC (“SAEV”), the corporate venturing subsidiary of Saudi Aramco, has led an investment into Novomer Inc., an emerging sustainable chemistry company pioneering a family of high performance, environmentally responsible polymers and chemical intermediates. All existing Novomer investors also participated in the financing.

BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test

BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3(R) Test

December 10, 2013

WALTHAM, Mass., Dec. 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company's galectin-3 blood test (analyte-specific CPT® Code 82777) at the amount of a crosswalked test (analyte-specific CPT® Code 84244) whose 2014 national limitation amount is $30.01. This national limitation amount will replace the galectin-3 blood test's national limitation amount of $17.80 that was effective in 2013.

Agios Presents Preclinical Data from Lead Programs at American Society of Hematology Annual Meeting

Agios Presents Preclinical Data from Lead Programs at American Society of Hematology Annual Meeting

December 9, 2013

Preclinical In Vivo Efficacy Demonstrated for IDH Inhibitors in Patient-Derived Leukemia Models

CAMBRIDGE, Mass. & NEW ORLEANS--(BUSINESS WIRE)-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that data from its lead programs were highlighted at the American Society of Hematology (ASH) Annual Meeting this week in New Orleans.